Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p>The Advisory Committee on Immunization Practices recently approved use of the 9-valent HPV vaccine for persons ages 27-45 years. The recommendation to expand use of the vaccine comes as findings from a large meta-analysis indicate that the HPV vaccine has substantially reduced infections and precancerous lesions.&nbsp;Providers are encouraged to discuss the potential benefits of HPV vaccination with patients in the mid-age category, addressing the reduced efficacy compared to vaccination within the younger target age range, as well as the reduced risk of high-grade disease and cervical cancer.</p>

ACIP Recommends HPV Vaccination for Older Men and Women